8.69
+3.08%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Grifols SA ADR
Its shares trade under the ticker GRFS. It has been listed since 17 May 2006. In the fiscal year to 31 December 2025, it reported revenue of $8.34bn and net income of $445.6m. At that date it held total assets of $22.79bn and shareholders' equity of $6.08bn.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 May 2006
- Employees
- 25,247
- Website
- grifols.com ↗
- Head office
- 1585 BROADWAY, NEW YORK, NY, 10036
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Grifols SA ADR operates in the Health Care sector with 25247 employees across multiple countries.
- Biopharma segment provides hemoderivatives for immunology and infectious disease treatments.
- Diagnostic segment markets testing equipment and reagents in the United States and Europe.
Weaknesses
- Grifols SA ADR's business is concentrated in the Health Care industry with limited diversification.
- The company relies on plasma-derived medicines which face regulatory scrutiny in multiple countries.
- Diagnostic segment's equipment sales are dependent on hospital procurement cycles.
Opportunities
- Grifols SA ADR can expand its Biopharma segment into emerging markets like Asia Pacific.
- Increasing demand for plasma-derived treatments in Europe offers growth potential.
- The Diagnostic segment can leverage new testing technologies for infectious disease diagnostics.
Threats
- Regulatory changes in the United States could impact plasma-derived medicine approvals.
- Competition from other Health Care companies in the European market is intensifying.
- Economic downturns may reduce hospital spending on diagnostic equipment and services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.